Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2011

View Archived Issues

Novel pyridin-2-ylmethylamine derivatives inhibit beta-amyloid aggregation in vitro

Shionogi & Co. presents new endothelial lipase inhibitors

Scientists at Bristol-Myers Squibb synthesize new HCV NS5A inhibitors

New aminopyrimidine gamma-secretase modulators show promise as AD therapeutics in vivo

Novel inhibitors of tyrosine-protein kinase SYK patented

Activity in models of AD observed with new small-molecule beta-amyloid toxicity inhibitor

Meiji Seika discloses new triterpene derivatives for HCV infection

Phase I tolerability data presented on CHF-5074

New estrogen-related receptor-alpha inverse agonists reported

Graceway Pharmaceuticals gains FDA approval for Zyclara cream

Seek completes proof-of-efficacy phase Ib/II trial of HIV-v vaccine

Phase II study begins for CNV-1014802 in pain

Roche to acquire mtm laboratories

Pfizer withdraws application to extend Macugen indication in E.U.

Novartis launches Exelon patch in Japan

Janssen launches Tramcet combination tablet in Japan

FDA clears Luminex's xTAG RVP FAST frontline respiratory panel

BrainStorm Cell Therapeutics and U.S. medical centers prepare for ALS trial collaboration

FDA committee issues opinion on approval of dapagliflozin for type 2 diabetes

Allergan enters definitive agreement to acquire Vicept Therapeutics

Alkermes provides update on merger and product portfolio

Galapagos small-molecule SARM enters proof-of-mechanism phase I trial

Cel-Sci and Teva Pharmaceutical extend Multikine licensing agreement

Shionogi to acquire nine marketed products from Victory Pharma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.